�°Ĳʹ��

Medicines Intelligence

Personalise

About us

The Medicines Intelligence Research Program is a leading research hub on quality use of medicines - with expertise in analysis of real-world data, sophisticated pharmacoepidemiologic methods, and pathways for knowledge translation. Our goal is to improve quality use of medicines and reduce medicine-related harm. Our multidisciplinary team partners with clinicians, policy makers and consumers to generate real-world evidence about the use and impact of medicines in routine clinical care. Our research leads to smarter and safer medicines use, improved health system performance, and better individual and population health.

Our Strengths

quality use of medicines
safety and effectiveness of medicines
increasing the use of evidence in policy and practice
evaluating health policies and programs
value and waste in health care
management of chronic disease and multimorbidity
uptake of new technologies
guideline concordant care

Our projects include research into medicines, from cancer and cardiovascular to psychotropic, opioids and antiretrovirals. Other projects focus on applying a health-system lens to improve equity in care and health outcomes.

Our people

Professor of Health Systems & Theme Principal, Health Systems Research

Michael Falster

Associate Professor, Heart Foundation Future Leader Fellow

Adjunct Professor & Senior Research Fellow

Senior Biostatistician

Benjamin Daniels

Senior Research Fellow, Cancer Institute NSW Early Career Fellow, Medicines Intelligence CRE Research Fellow

Juliana de Oliveira Costa

Lecturer

Natasha Hirschhorn-Edwards

MI-CRE Program and Communications Manager

Malcolm Gillies

Senior Biostatistician

Melisa Litchfield

Data Manager

Senior Research Associate

Associate Professor

Postdoctoral Fellow

Research Associate

Research Manager (Analytics)

Research Manager

Our research programs

Medicines Intelligence Centre of Research Excellence

The CRE provides an opportunity for researchers in institutions across the country to collaborate more closely on key research priorities and accelerate the development and translation of evidence about real-world medicine use and outcomes.

Cardiometabolic Medicines

Our research aims to improve medicine use and outcomes for people with heart disease in Australia. We investigate treatment of conditions such as hypertension, diabetes, obesity, acute myocardial infarction, heart failure, atrial fibrillation and surgical interventions.

Opioids in Pregnancy

The Prescription Opioids in the Perinatal Period (POPP) Program harnesses the power of ‘big data’ to generate real-world evidence regarding the use and safety of prescription opioids before, during and after pregnancy.